Clin2
NCT07204249Possibly a fitRecruiting

Testing a diabetes drug to help stop meth use

Methamphetamine-dependence

Treatments studied

Part of Mental health clinical trials.

This study tests whether a medication called 'Glutide' (a GLP-1 agonist, similar to drugs used for diabetes) can help people who want to stop or cut down on methamphetamine. It's for those with moderate to severe meth use disorder who have used meth on at least 15 of the past 30 days.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
162 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be between 18 and 65 years old.
  • You must have used meth on at least 15 of the past 30 days and test positive for meth in a urine test.
  • You must want to stop or reduce your meth use.
  • Your BMI must be 25 or higher (overweight).
  • You cannot be pregnant, plan to become pregnant, or breastfeed, and must agree to use effective birth control if applicable.
  • You must not have certain health conditions like diabetes, heart failure, pancreatitis, or uncontrolled high blood pressure.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07509112Not yet recruiting· Phase 2
Semaglutide for people with methamphetamine use disorder

This trial tests if semaglutide (a medicine used for diabetes and weight loss) can help reduce methamphetamine use. If you qualify, you might get the study drug and support to help you cut back or stop using methamphetamine.

Darlinghurst, New South Wales
NCT07227948Recruiting· Phase 2
Testing semaglutide for cocaine use disorder

This study tests whether semaglutide, a medication used for weight management, can help reduce cocaine use in people with cocaine use disorder. You may qualify if you have a body mass index (BMI) of 25 or higher and recently used cocaine.

Houston, Texas
NCT07825857Not yet recruiting· Phase 2
Tirzepatide for reducing methamphetamine use

This study tests whether tirzepatide, a medication that may help reduce cravings and weight, can help people who use methamphetamine cut down or stop. It aims to find a new treatment option for methamphetamine use disorder.

Los Angeles, California
NCT06548490Recruiting· Phase 2
Semaglutide for Opioid Use Disorder

This study tests whether a once-weekly injection of semaglutide (a GLP-1 receptor agonist) can reduce opioid use in people who are already on buprenorphine or methadone but still using opioids. It lasts about 19 weeks.

Baltimore, Maryland
NCT06639464Recruiting· Phase 2
Semaglutide for improving opioid recovery outcomes

This study tests whether semaglutide (a medication used for weight management) can help people on buprenorphine or methadone reduce their opioid use. If it works, it could provide additional support during recovery.

Boston, Massachusetts
NCT07523633Recruiting· Phase 2
Semaglutide to help reduce cannabis use disorder

This trial tests whether a medication called semaglutide (used for weight management) can help adults with cannabis use disorder cut down or stop using cannabis. Researchers want to see if it reduces cravings and use while also monitoring overall health.

Frederiksberg

Hear when a new Methamphetamine-dependence trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.